Ratepayers in Belfast have suffered a significant rise in their bills of more than 22% in the last four years, with the ...
Zacks Investment Research on MSN11h
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/YSage Therapeutics, Inc. SAGE reported a loss of $1.56 per share for the fourth quarter of 2024, wider than the Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback